###begin article-title 0
###xml 39 41 39 41 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2C</sub>
###xml 51 52 51 52 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
Multiple interactions between the alpha2C- and beta1-adrenergic receptors influence heart failure survival
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 38 39 35 36 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 238 240 231 233 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2C</sub>
###xml 456 462 449 455 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRB1 </italic>
###xml 466 472 459 465 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRA2C</italic>
###xml 537 545 <span type="species:ncbi:9606">patients</span>
Persistent stimulation of cardiac beta1-adrenergic receptors by endogenous norepinephrine promotes heart failure progression. Polymorphisms of this gene are known to alter receptor function or expression, as are polymorphisms of the alpha2C-adrenergic receptor, which regulates norepinephrine release from cardiac presynaptic nerves. The purpose of this study was to investigate possible synergistic effects of polymorphisms of these two intronless genes (ADRB1 and ADRA2C, respectively) on the risk of death/transplant in heart failure patients.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 31 38 31 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRA2C </italic>
###xml 68 74 68 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRB1 </italic>
###xml 140 148 <span type="species:ncbi:9606">patients</span>
Sixteen sequence variations in ADRA2C and 17 sequence variations in ADRB1 were genotyped in a longitudinal study of 655 white heart failure patients. Eleven sequence variations in each gene were polymorphic in the heart failure cohort. Cox proportional hazards modeling was used to identify polymorphisms and potential intra- or intergenic interactions that influenced risk of death or cardiac transplant. A leave-one-out cross-validation method was utilized for internal validation.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 23 30 23 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRA2C </italic>
###xml 56 62 56 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRB1 </italic>
Three polymorphisms in ADRA2C and five polymorphisms in ADRB1 were involved in eight cross-validated epistatic interactions identifying several two-locus genotype classes with significant relative risks ranging from 3.02 to 9.23. There was no evidence of intragenic epistasis. Combining high risk genotype classes across epistatic pairs to take into account linkage disequilibrium, the relative risk of death or transplant was 3.35 (1.82, 6.18) relative to all other genotype classes.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 55 62 55 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRA2C </italic>
###xml 66 72 66 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRB1 </italic>
###xml 143 151 <span type="species:ncbi:9606">patients</span>
Multiple polymorphisms act synergistically between the ADRA2C and ADRB1 genes to increase risk of death or cardiac transplant in heart failure patients.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 244 245 244 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 246 247 246 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 269 270 265 266 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 298 301 290 293 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 310 312 298 300 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2C</sub>
###xml 534 535 522 523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 536 537 524 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 592 593 577 578 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 620 621 602 603 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 806 807 788 789 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 852 853 831 832 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1015 1016 994 995 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 1389 1390 1368 1369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 1391 1393 1370 1372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 452 457 <span type="species:ncbi:10090">mouse</span>
Congestive heart failure can be caused by a wide array of myocardial insults. Although this etiological heterogeneity has yet to be well characterized, the role of neurohormonal pathways in the progression of heart failure is well established [1-3]. Prejunctional alpha2-adrenergic receptors (alpha2A and alpha2C) regulate the release of norepinephrine from cardiac sympathetic nerves in a negative feedback manner. When these receptors are ablated in mouse models, uncontrolled norepinephrine release causes a lethal cardiomyopathy [4,5]. Moreover, the released norepinephrine activates beta1-adrenergic receptors (beta1AR) expressed on cardiac myocytes which are coupled to stimulatory G-proteins that propagate signals to downstream effectors such as adenylyl cyclase, ion channels, and phospholipases [6]. Prolonged activation of cardiomyocyte beta1AR signaling by any number of pharmacologic or genetic means typically results in hypertrophy, ventricular dysfunction, ventricular remodeling, or frank failure [7]. Thus, sympathetic activation of the heart is coordinated in part by these two adrenergic receptors, in which genetic variation of expression or function could act to modify the progression of heart failure. And indeed, substantial variation in the progression, mortality, and treatment response of heart failure between otherwise similar individuals is well recognized [8-10].
###end p 11
###begin p 12
###xml 76 77 73 74 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 86 91 83 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRB1</italic>
###xml 226 228 223 225 <sub xmlns:xlink="http://www.w3.org/1999/xlink">s </sub>
###xml 250 252 247 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 339 341 336 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 371 373 368 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 374 376 371 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 393 395 390 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 433 435 430 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 584 586 581 583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 329 337 <span type="species:ncbi:9606">patients</span>
###xml 441 456 <span type="species:ncbi:10090">transgenic mice</span>
###xml 544 548 <span type="species:ncbi:10090">mice</span>
Previous studies of a common single nucleotide polymorphism C->G in the beta1AR gene (ADRB1) at codon 389, which results in an arginine for glycine substitution (Arg389Gly), have shown enhanced coupling of the Arg variant to Gs in recombinant cells [11]. Arg389 is associated with differential exercise capacity in heart failure patients [12], response to beta-blockers [13,14], hypertension [15], and risk of myocardial infarction [16]. In transgenic mice, the Arg variant has been associated with early enhanced cardiac function but in older mice a predisposition to heart failure [17].
###end p 12
###begin p 13
###xml 132 134 128 130 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2C</sub>
###xml 143 149 139 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRA2C</italic>
###xml 195 197 191 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 313 315 309 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 388 394 384 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRB1 </italic>
###xml 398 405 394 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRA2C </italic>
###xml 519 521 515 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 580 582 573 575 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 652 658 645 651 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRB1 </italic>
###xml 672 679 665 672 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRA2C </italic>
###xml 903 905 896 898 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 906 908 899 901 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 1114 1121 1107 1114 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRA2C </italic>
###xml 1159 1165 1152 1158 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRB1 </italic>
###xml 570 578 <span type="species:ncbi:9606">patients</span>
A common insertion/deletion polymorphism in African-Americans resulting in a consecutive four amino acid loss (322-325) in the alpha2CAR gene (ADRA2C) has been found to reduce receptor function [18], leading to a loss of normal synaptic autoinhibitory feedback and concomitant enhanced release of norepinephrine [19]. Given the potential synergistic effects of these polymorphisms in the ADRB1 and ADRA2C genes, two previous studies have investigated and identified epistatic interactions affecting heart failure risk [20] and response to beta-blockers in heart failure patients [21]. In both studies, only two putative functional polymorphisms (i.e., ADRB1 Arg389Gly and ADRA2C ins/del 322) were examined. Multiple additional polymorphisms in both of these two intronless genes have been recently identified and characterized in whole-gene transfection studies, some of which alter protein expression [22,23]. Here we examine whether there is evidence for more complex intragenic and intergenic epistatic effects on heart failure phenotypes and survival in these genes utilizing 16 DNA sequence variations in the ADRA2C and 17 DNA sequence variations in the ADRB1 genes.
###end p 13
###begin p 14
Intergenic epistasis, or interaction between two genes, occurs when the phenotypic effects of a variation in one gene is affected by a variation in a second gene. This could result from conformational changes that prevent physical interaction between the two gene products, or from a change in the ability of one gene to regulate the expression of the other or, the pathologic pathway involves both genes in a manner that their downstream effects converge to alter critical events. Intragenic epistasis occurs when a variation in one location of a gene influences the phenotype differently depending on other variations within the same gene. This type of epistasis is most notable when two different amino acid substitutions within a gene result in differentially functioning the resulting protein. However, it is also seen to have an effect on gene expression and processing.
###end p 14
###begin title 15
Methods
###end title 15
###begin title 16
Study Population
###end title 16
###begin p 17
###xml 326 328 326 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 329 331 329 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 702 703 702 703 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 32 40 <span type="species:ncbi:9606">patients</span>
###xml 709 714 <span type="species:ncbi:9606">human</span>
The 655 Caucasian heart failure patients were identified and enrolled in the study at the University of Cincinnati, Cincinnati, OH, between 1999 and 2004. The study was restricted to Caucasians because of the significant differences in the allele frequencies between those of African- and European-descent in these two genes [22,23], and a smaller number of potential black enrollees. Other enrollment criteria were: age of 18 to 80 years, left ventricular ejection fraction (LVEF) of less than 40%, and New York Heart Association heart failure class II-IV. The primary study endpoint was the combined event of death or cardiac transplantation. Descriptive statistics of this cohort are given in Table 1. The human study protocols were approved by the institutional review board of the University of Cincinnati, and subjects provided written informed consent.
###end p 17
###begin p 18
Descriptive statistics for the heart failure cohort
###end p 18
###begin title 19
Genotyping
###end title 19
###begin p 20
###xml 54 61 54 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRA2C </italic>
###xml 62 64 62 64 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 70 76 70 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRB1 </italic>
###xml 77 79 77 79 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 548 549 548 549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 582 589 582 589 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRA2C </italic>
###xml 631 637 631 637 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRB1 </italic>
###xml 714 720 714 720 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRA2C</italic>
###xml 739 744 739 744 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRB1</italic>
Sequence variants have been previously identified for ADRA2C [22] and ADRB1 [23] and the nomenclature used in these papers is retained in the current work to maintain consistency. Both genes are intronless, and the A of the initiation codon is denoted as +1, proceeding in the positive direction 5' -3' through the coding and 3' UTR. In the 5' -flanking region the most 3' non-coding nucleotide prior to the ATG is denoted as -1 and the numbering proceeds in the negative direction. The genotyping was performed on the variant sites shown in Table 2. For orientation purposes +1 of ADRA2C is nucleotide 2638 of AY605898, and +1 of ADRB1 is nucleotide 36085 of AL355543. The variants are deposited in the PharmGKB (ADRA2C) and SeattleSNPs (ADRB1) public databases ( and , respectively). Genotyping was performed on genomic DNA derived from blood samples, by sequencing PCR products spanning one or two variant positions, using an ABI 3730 sequencer. Variants detected by alignment to a reference were verified by visual electropherogram examination.
###end p 20
###begin p 21
Summary of the SNP frequency distributions
###end p 21
###begin title 22
Statistical Methods
###end title 22
###begin p 23
###xml 134 136 134 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 186 188 186 188 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 199 201 199 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 239 241 239 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
Allele frequencies were estimated using standard gene counting methods. Hardy-Weinberg disequilibrium was tested using Weir's method [24]. Linkage disequilibrium was assessed using the r2 statistic [24]. Cox Proportional Hazards modeling [25]. was used to test for significant effects for each polymorphism (separately) and pairwise epistatic effects after adjustment for age at initial diagnosis, beta-blocker usage, hypertension status, and sex. Genotypes for each polymorphism were coded using two dummy variables where the most frequent genotype was considered the reference group. Epistasis was assessed by including interaction terms into the Cox models.
###end p 23
###begin p 24
###xml 129 131 129 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 488 490 488 490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 691 692 691 692 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 383 390 <span type="species:ncbi:9606">patient</span>
To adjust for multiple testing we used Storey's modification of the false discovery rate (FDR) method of Benjamini and Hochberg [26] that takes into account the correlation among tests due to linkage disequilibrium. We used an FDR cutpoint of 0.30. To assess whether the information from the Cox proportional hazards modeling of genetic effects provides a useful prediction of a new patient's risk of death or cardiac transplant, we implemented a leave-one-out cross-validation approach [27]. Each individual was sequentially left out and a Cox proportional hazards model for time from study enrollment to death or cardiac transplant was estimated. Using the coefficients estimated with the n-1 individuals, a survival risk was calculated for the individual left out. These risks were then used as the predictor in a new Cox proportional hazards model. Because each individual was omitted from the model used to calculate their survival risk, the performance of a model using these risks as predictors approximates the predictive ability of the association in an independent sample drawn from the same population.
###end p 24
###begin p 25
In order to assess the overall impact of high-risk two-locus genotype classes on risk of death or cardiac transplant, a pooling procedure was performed. If an individual possessed one or more two-locus genotype class that had a relative risk whose 95% confidence interval was greater than 1.0, they were assigned the label "has high-risk genotype." All other individuals were assigned the label "does not have high-risk genotype." Cox proportional hazards modeling was then performed with this label as the explanatory variable.
###end p 25
###begin title 26
Results
###end title 26
###begin p 27
###xml 184 185 181 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 527 528 524 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 720 727 717 724 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRA2C </italic>
###xml 765 771 762 768 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRB1 </italic>
###xml 800 801 797 798 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 846 853 843 850 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRA2C </italic>
###xml 882 888 879 885 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRB1 </italic>
###xml 977 983 974 980 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRA2C</italic>
###xml 996 1002 993 999 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRA2C</italic>
###xml 1022 1027 1019 1024 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRB1</italic>
###xml 1043 1048 1040 1045 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRB1</italic>
###xml 1205 1206 1202 1203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
The 655 subject heart failure cohort was 69.2% male, with 47.9% having a history of hypertension, 84.0% receiving ACE inhibitor therapy and 69.6% receiving beta-blocker therapy (Table 1). Ischemic cardiomyopathies made up 39.5% of the cohort, idiopathic dilated cariomyopaties comprised 58.3% of the cohort, and the remaining 2.1% of the cohort had other causes of heart failure, such as primary valvular defects. They had an average age of heart failure onset of 53.8 years and an average follow-up time of 3.16 years. Figure 1 shows a Kaplan-Meier curve of time from heart failure diagnosis to death or cardiac transplant for this cohort. The minor alleles and the frequencies of the 16 DNA sequence variations in the ADRA2C and 17 DNA sequence variations in the ADRB1 genes are displayed in Table 2. Eleven of the 16 variants genotyped in the ADRA2C gene and 11 of the 17 in the ADRB1 gene had frequencies greater than 1% and are considered polymorphic. Four polymorphisms, ADRA2C(-2579 T/C), ADRA2C(+964/965 ins/del), ADRB1(-517 T/C), and ADRB1(+145 A/G), were significantly out of Hardy Weinberg equilibrium (HWE) (P < 0.05). The linkage disequilibrium between polymorphisms is illustrated in Figure 2 and indicates that several polymorphisms within each gene have significant frequency correlations.
###end p 27
###begin p 28
Kaplan-Meier curve of time from heart failure diagnosis to death or cardiac transplant.
###end p 28
###begin p 29
###xml 32 39 32 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRA2C </italic>
###xml 85 91 85 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRB1 </italic>
A. Linkage disequilibrium among ADRA2C polymorphisms B. Linkage disequilibrium among ADRB1 polymorphisms.
###end p 29
###begin p 30
###xml 229 230 229 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
Given the large number of tests for main effects and epistatic effects using these 22 polymorphic loci we used both the false discovery rate and cross-validation methods to reduce the probability of false positive results. Table 3 provides a summary of the tests of association between the polymorphism and age of onset, LVEF, LV mass, and survival. Overall, only two polymorphisms had significant main effects on the survival distribution and 8 pairs of polymorphisms had epistatic effects on survival that were significant (after adjustment by FDR) and cross-validated.
###end p 30
###begin p 31
Summary of the significant, false discovery rate adjusted, and cross-validated ADRA2C and ADRB1 polymorphism effects and interactions on age of onset, LVmass, LVEF, and heart failure survival
###end p 31
###begin p 32
* LVMass was adjusted for age of onset, sex, height, weight, hypertension
###end p 32
###begin p 33
** LVEF was adjusted for age of onset, sex
###end p 33
###begin p 34
*** For survival analysis, Risk Index was used to cross-validate, P-value for Cox model with Risk Index <0.1 is considered as crossvalidated. For continuous outcomes, 4-fold CV was used. Press-Rsquared >0.005 (SNP univ model) or Press-Rsquared for full model >0 and Press-Rsquared Difference between full model and submodel >0.005 (Epistasis) is considered to be crossvalidated for interaction.
###end p 34
###begin p 35
###xml 80 81 80 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 136 142 136 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRA2C</italic>
###xml 158 164 158 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRA2C</italic>
###xml 529 535 529 535 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRA2C</italic>
###xml 558 563 558 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRB1</italic>
###xml 723 729 723 729 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRA2C</italic>
###xml 744 749 744 749 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRB1</italic>
###xml 934 940 934 940 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRA2C</italic>
###xml 955 960 955 960 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRB1</italic>
###xml 1072 1078 1072 1078 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRA2C</italic>
###xml 1094 1099 1094 1099 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRB1</italic>
###xml 1261 1267 1261 1267 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRA2C</italic>
###xml 1283 1288 1283 1288 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRB1</italic>
###xml 1395 1401 1395 1401 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRA2C</italic>
###xml 1417 1422 1417 1422 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRB1</italic>
###xml 1505 1511 1505 1511 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRA2C</italic>
###xml 1576 1582 1576 1582 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRB1 </italic>
The relative risks (RR) associated with these polymorphisms are listed in Table 4. The two polymorphisms with single locus effects were ADRA2C(-1692 T/G) and ADRA2C(+964/965 ins/del). However, both of these polymorphisms were involved in significant epistatic interactions making the interpretation of the relative risks of their main effects impossible. Even though we equally tested for interactions within and among the two genes, somewhat surprisingly, we only found evidence of intergenic epistasis. The interaction between ADRA2C(+964/965 ins/del) and ADRB1(+145 A/G) arises from the 10:AG genotype class having elevated risk of death or transplant with RR = 5.12 (2.66,9.88). With respect to the interaction between ADRA2C(-230 T/C) and ADRB1(-517 T/C), the TC:CT genotype class has much higher risk of death or transplant with RR = 8.31 (3.32, 20.75) compared to the reference genotype class of TT:TT. The interaction between ADRA2C(-230 T/C) and ADRB1(-2297 T/G) appears to be due to the TC:TG genotype class (RR = 9.23 (3.67,23.16)), and the interaction between ADRA2C(-1692 T/G) and ADRB1(+145 A/G) is associated with an increased risk of death or transplant in the TG:AG genotype class with RR = 4.59 (2.31, 9.12). Likewise, the interaction between ADRA2C(-1692 T/G) and ADRB1(-3641 C/T) identifies the TG:CT genotype as the high risk group with RR = 3.56 (1.80, 7.05). Finally, the ADRA2C(-1692 T/G) and ADRB1(-3255 A/C) polymorphism appear to be interacting and again the TG genotype of the ADRA2C(-1692 T/G) gene has a significant increase risk in a particular ADRB1 genotype background - namely, AC genotype - such that the TG:AC genotype class has a relative risk of 3.02(1.53,5.97).
###end p 35
###begin p 36
###xml 57 64 57 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRA2C </italic>
###xml 68 74 68 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRB1 </italic>
FDR Significant and Cross-Validated Epistatic Effects of ADRA2C and ADRB1 polymorphisms on survival
###end p 36
###begin p 37
* RR is significant at alpha < 0.05
###end p 37
###begin p 38
###xml 85 98 85 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a posteriori </italic>
Given some degree of non-independence among these epistatic effects, we performed an a posteriori pooling of all high risk two locus genotype classes with RR's whose 95% confidence interval exceed 1.0 to attempt to identify the extent of overlap between the effects from the pairs of loci. These were compared to all other genotype classes combined, which provides a way to interpret these very specific sets of polymorphisms as if being used clinically. Here we found that the combined relative risk was 3.35 (1.82, 6.18).
###end p 38
###begin title 39
Discussion
###end title 39
###begin p 40
###xml 63 70 63 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRA2C </italic>
###xml 74 80 74 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRB1 </italic>
###xml 250 252 250 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 253 255 253 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 256 258 256 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 276 278 276 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 308 310 308 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 311 313 311 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 314 316 314 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 317 319 317 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 157 165 <span type="species:ncbi:9606">patients</span>
###xml 223 228 <span type="species:ncbi:9606">human</span>
###xml 229 236 <span type="species:ncbi:9606">patient</span>
In this study, we identified multiple polymorphisms within the ADRA2C and ADRB1 genes that interact to increase risk of death or transplant in heart failure patients. We investigated these genes because numerous studies in human patient populations [20,12,14], animal models [17], and in vitro cell systems [18,11,22,23] have demonstrated their relevance to heart failure phenotypes or receptor expression/function.
###end p 40
###begin p 41
###xml 256 258 256 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 504 506 504 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 554 562 <span type="species:ncbi:9606">patients</span>
As noted in the Results, four of the polymorphism significantly deviated from Hardy-Weinberg equilibrium. However, a previous study that genotyped the ADRA2C polymorphisms in a cohort of unaffected individuals did not show evidence of deviations from HWE [22]. Similarly, genotyping of the ADRB1 polymorphisms in unaffected individuals for the Seattle SNPs database  do not show significant deviations from HWE. The HW deviations we observed could be due to an underlying association with heart failure [28] since our sample is exclusively heart failure patients and these genes have been previously associated with this disease, but random chance and genotyping error cannot be excluded.
###end p 41
###begin p 42
###xml 9 10 5 6 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 153 154 149 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 374 375 366 367 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 493 494 482 483 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 499 500 488 489 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 513 520 502 509 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRA2C </italic>
###xml 589 595 578 584 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRA2C</italic>
###xml 657 659 642 644 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2C</sub>
###xml 694 696 679 681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 759 761 744 746 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 907 909 892 894 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 1002 1004 983 985 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2C</sub>
###xml 1072 1074 1049 1051 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2C</sub>
###xml 1166 1168 1143 1145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1337 1338 1311 1312 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1608 1610 1582 1584 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 1682 1683 1653 1654 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1873 1875 1844 1846 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 1971 1977 1942 1948 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRB1 </italic>
###xml 2022 2024 1993 1995 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 2081 2082 2049 2050 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 358 362 <span type="species:ncbi:10090">mice</span>
###xml 507 512 <span type="species:ncbi:9606">human</span>
###xml 1087 1091 <span type="species:ncbi:10090">mice</span>
###xml 1616 1631 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1672 1677 <span type="species:ncbi:9606">human</span>
The alpha2ARs expressed on the presynaptic cardiac sympathetic nerves inhibit the release of norepinephrine when they are bound by the neurotransmitter [5], and thus provide a mechanism to regulate release of the neurotransmitter as sympathetic nervous system activity markedly increases in progressive heart failure. And indeed, in studies of gene-targeted mice where alpha2ARs have been ablated, severe cardiomyopathy results due to norepinephrine cardiotoxicity exerted through myocyte beta1ARs [5]. The human ADRA2C ins/del polymorphism previously denoted Del322-325, and here denoted ADRA2C(+964/965 ins/del) significantly reduces the function of alpha2CAR receptors in transfected cells [18]. While Caucasians have a very low prevalence of this allele [20] it appears that other common polymorphisms within this racial group, in the promoter and 3' UTR region of the gene, affect receptor expression [22]. Of note, evidence suggests that there are few "spare receptors" in the complement of alpha2CARs expressed in cardiac presynaptic nerves since heterozygous alpha2CAR knock-out mice (~50% less receptor) also develop cardiomyopathy under pressure overload [29]. Thus relatively small changes in expression due to polymorphisms may have physiologically relevant effects on the heart during heart failure progression. For the beta1AR, the most frequently studied polymorphic variation is at nucleotide 1165, where Arg or Gly can be commonly found at amino acid 389. This lies within a G-protein coupling domain, and in transfected cells the Arg variant exhibits enhanced coupling to adenylyl cyclase [11]. In transgenic mice, with matched cardiac expression of the human beta1AR Arg or Gly389 receptors, Arg hearts have enhanced contractility, but progress to failure by 9-months of age, while Gly hearts show less contractile enhancement and no pathologic effects [17]. The Arg389 phenotype also revealed a gene dose-response, and given that promoter SNPs of the ADRB1 gene alter expression in cell-based systems [23], the potential for cardiac relevance of non-coding beta1AR SNPs is apparent.
###end p 42
###begin p 43
###xml 49 56 49 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRA2C </italic>
###xml 64 70 64 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRB1 </italic>
###xml 213 215 213 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 327 329 327 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 523 529 523 529 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRA2C</italic>
###xml 591 597 591 597 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRB1 </italic>
###xml 656 662 656 662 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRA2C</italic>
###xml 734 740 734 740 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRB1 </italic>
###xml 789 795 789 795 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRB1 </italic>
###xml 880 887 880 887 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRA2C </italic>
###xml 972 979 972 979 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRA2C </italic>
###xml 1014 1020 1014 1020 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRB1 </italic>
###xml 232 239 <span type="species:ncbi:9606">patient</span>
###xml 495 503 <span type="species:ncbi:9606">patients</span>
The previous studies of interactions between one ADRA2C and one ADRB1 polymorphism illustrate that the physiological effects of variations in these two genes act synergistically to increase risk of heart failure [20] and influences patient responsiveness to beta-blocker therapy as assessed by short-term improvements in LVEF [21]. Our study indicates that there may be several other polymorphisms within these genes that have important physiological and clinical consequences for heart failure patients. Specifically, the ADRA2C(-1692 T/G) was involved in three epistatic interactions with ADRB1 polymorphisms (+145 A/G, -3641 C/T, and -3255 A/C) and the ADRA2C(-230 T/C) polymorphism was involved in two epistatic interactions with ADRB1 polymorphisms (-2297 T/G and -517 T/C). Only one ADRB1 polymorphism (+145 A/G) was involved in more than one epistatic interaction with the ADRA2C polymorphisms (-1692 T/G and +964/965 ins/del). In total, three polymorphisms in the ADRA2C gene and five polymorphisms in the ADRB1 gene appear to be implicated in epistatic effects on heart failure survival.
###end p 43
###begin p 44
Because of the relatively large number of polymorphisms investigated in each gene one natural analytical approach might have been to investigate haplotypes within each gene and to test for potential interaction between haplotypes in their influence on risk. However, one of the main drawbacks of such an approach is reducing the haplotype space to the relevant set with phenotypic effects that could potentially interact within or across genes. Since we did not find any evidence of significant intragenic epistasis, it becomes even more difficult to analyze the diverse set of haplotypes - many with low frequency - to identify potentially relevant interactions across genes.
###end p 44
###begin p 45
###xml 111 113 111 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 598 600 598 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 754 756 754 756 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 820 822 820 822 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 823 825 823 825 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 944 946 944 946 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 1003 1005 1003 1005 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 1019 1021 1019 1021 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 1022 1024 1022 1024 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 1047 1049 1047 1049 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
One of the short-comings of genetic association studies is that they have often failed to replicate and Manly [30] suggests that internal validation, common to good experimental practices, is one way to avoid the publication of spurious findings. In our study, we used cross-validation methods to significantly reduce the chance of false positives. Cross-validation methods were developed as a way to incorporate a measure of predictive accuracy (and correspondingly, a measure of prediction error) for an estimated model based on its performance predicting the outcome for independent test cases [31]. During the last decade, cross-validation methods have been used widely for everything from robust variable selection in gene expression array studies [32] to reducing false positives in gene-gene interaction studies [33,34] to evaluating the predictive accuracy of molecular or genetic classifiers of disease before clinical implementation [35]. It has become a standard in the field of metabolomic [36], proteomic [37,38], and transcriptomic [39] studies because of its ease of execution and its emphasis on prediction in independent test cases as a method of discriminating between true associations and false associations.
###end p 45
###begin p 46
###xml 104 111 104 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRA2C </italic>
###xml 167 173 167 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRAB1</italic>
###xml 411 413 411 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 414 416 414 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 417 419 417 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 420 422 420 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 444 451 444 451 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRA2C </italic>
###xml 518 525 518 525 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRAB1 </italic>
###xml 559 561 555 557 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2C</sub>
###xml 604 610 600 606 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRA2C</italic>
###xml 757 759 753 755 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 770 776 766 772 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRAB1</italic>
###xml 914 915 907 908 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 930 932 923 925 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 1032 1033 1022 1023 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1124 1126 1114 1116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 1980 1982 1966 1968 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2C</sub>
###xml 1993 1994 1976 1977 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1378 1386 <span type="species:ncbi:9606">patients</span>
###xml 1892 1900 <span type="species:ncbi:9606">patients</span>
The epistatic interactions identified here occur between -1692, -230, and the +964/965 polymorphisms of ADRA2C and -3641, -3255, -2297, -517 and +145 polymorphisms in ADRAB1. We have previously generated constructs that mimic these polymorphisms and by transient transfection of cells ascertained expression phenotypes (5' and 3' -flanking regions) or signaling phenotypes (nonsynonymous coding polymorphisms) [11,22,23,18]. All but one of the ADRA2C 5' promoter and 5' UTR polymorphisms found here that interact with ADRAB1 have been found to influence alpha2CAR expression in these model systems. (The ADRA2C(-1692) polymorphism has not been studied in this manner.) And, the +964/965 deletion polymorphism results in depressed agonist-promoted function [18]. For the ADRAB1, the aforementioned polymorphisms of the promoter region (except for -1294 which has not been studied) have also been shown to alter beta1AR expression [23]. The nonsynonymous polymorphism at nucleotide position +145 (representing Gly49) results in a beta1AR that undergoes enhanced agonist-promoted downregulation compared to the Ser49 receptor [40], an important phenotype since downregulation is a protective mechanism in heart failure. Taken together, then, there is biologic plausibility in the epistatic interactions that were observed. The fact that there is a relatively large fraction of the patients that do not have these specific combinations, and yet they do display variability in heart failure progression, indicates additional genetic (and likely non-genetic) causes for heterogeneity. Within the axis which we are currently exploring, there are a number of other genes to be considered. As additional information from fine mapping and cell-based studies is obtained, there is the possibility for enhanced predictive power and an assignment of risk alleles for a greater percentage of heart failure patients. Nevertheless, the current work shows that epistatic interactions between alpha2CAR and beta1AR polymorphisms affect heart failure survival, and further confirm the notion that this complex syndrome is modified by multiple polymorphisms in multiple genes.
###end p 46
###begin title 47
Conclusion
###end title 47
###begin p 48
###xml 74 81 74 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRA2C </italic>
###xml 85 91 85 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRB1 </italic>
###xml 171 178 171 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRA2C </italic>
###xml 182 188 182 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRB1 </italic>
###xml 259 267 <span type="species:ncbi:9606">patients</span>
Although we did not observe intragenic epistatic interactions between the ADRA2C and ADRB1 genes, we did observe multiple polymorphisms acting synergistically between the ADRA2C and ADRB1 genes to increase risk of death or cardiac transplant in heart failure patients. This underscores the complexity of the genetic factors that affect the progression of this syndrome.
###end p 48
###begin title 49
Competing interests
###end title 49
###begin p 50
The authors declare that they have no competing interests.
###end p 50
###begin title 51
Authors' contributions
###end title 51
###begin p 52
###xml 191 198 191 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRA2C </italic>
###xml 202 208 202 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRB1 </italic>
###xml 470 477 470 477 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRA2C </italic>
###xml 481 487 481 487 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADRB1 </italic>
SLRK performed statistical analysis and drafted the manuscript. RK performed statistical analysis and assisted in drafting the manuscript. MK, BA, and GG developed genotyping methods for the ADRA2C and ADRB1 polymorphisms and performed the genotyping of the subjects. HH and LW recruited subjects and interpreted echocardiogram results. KC managed the subject clinical and endpoint data. GWD designed the study and assisted in drafting the manuscript. SL identified the ADRA2C and ADRB1 polymorphisms and their haplotypes, developed genotyping methods, participated in the design of the study and interpretation of results, and assisted in drafting the manuscript. All authors read and approved the final manuscript.
###end p 52
###begin title 53
Pre-publication history
###end title 53
###begin p 54
The pre-publication history for this paper can be accessed here:
###end p 54
###begin p 55

###end p 55
###begin title 56
Acknowledgements
###end title 56
###begin p 57
###xml 51 99 51 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Genetic and Molecular Signaling in Heart Failure</italic>
The present study was funded by NHLBI P50 HL77101, Genetic and Molecular Signaling in Heart Failure.
###end p 57
###begin article-title 58
Why does the myocardium fail? Insights from basic science
###end article-title 58
###begin article-title 59
Mechanistic and clinical rationales for using beta-blockers in heart failure
###end article-title 59
###begin article-title 60
Beta-adrenergic receptors in the failing heart: the good, the bad, and the unknown
###end article-title 60
###begin article-title 61
###xml 87 92 <span type="species:ncbi:9606">human</span>
Evidence for functional presynaptic alpha-2 adrenoceptors and their down-regulation in human heart failure
###end article-title 61
###begin article-title 62
Two functionally distinct alpha2-adrenergic receptors regulate sympathetic neurotransmission
###end article-title 62
###begin article-title 63
###xml 104 109 <span type="species:ncbi:9606">human</span>
Beta 1- and beta 2-adrenergic receptor-mediated adenylate cyclase stimulation in nonfailing and failing human ventricular myocardium
###end article-title 63
###begin article-title 64
###xml 63 67 <span type="species:ncbi:10090">mice</span>
###xml 72 75 <span type="species:ncbi:9606">men</span>
Manipulating cardiac contractility in heart failure: Data from mice and men
###end article-title 64
###begin article-title 65
###xml 59 67 <span type="species:ncbi:9606">patients</span>
Ejection fraction improvement by beta-blocker treatment in patients with heart failure: An analysis of studies published in the literature
###end article-title 65
###begin article-title 66
###xml 64 72 <span type="species:ncbi:9606">patients</span>
Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): Randomised controlled trial
###end article-title 66
###begin article-title 67
###xml 41 49 <span type="species:ncbi:9606">patients</span>
Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study
###end article-title 67
###begin article-title 68
###xml 70 75 <span type="species:ncbi:9606">human</span>
A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor
###end article-title 68
###begin article-title 69
Polymorphisms of the beta1-adrenergic receptor predict exercise capacity in heart failure
###end article-title 69
###begin article-title 70
Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol
###end article-title 70
###begin article-title 71
###xml 121 126 <span type="species:ncbi:9606">human</span>
A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure
###end article-title 71
###begin article-title 72
Polymorphism in the beta(1)-adrenergic receptor gene and hypertension
###end article-title 72
###begin article-title 73
###xml 30 35 <span type="species:ncbi:9606">human</span>
###xml 65 73 <span type="species:ncbi:9606">patients</span>
Arg389Gly polymorphism of the human beta1-adrenergic receptor in patients with nonfatal acute myocardial infarction
###end article-title 73
###begin article-title 74
Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure
###end article-title 74
###begin article-title 75
###xml 79 84 <span type="species:ncbi:9606">human</span>
A four amino acid deletion polymorphism in the third intracellular loop of the human alpha 2C-adrenergic receptor confers impaired coupling to multiple effectors
###end article-title 75
###begin article-title 76
###xml 109 115 <span type="species:ncbi:9606">humans</span>
Sympathoneural and adrenomedullary functional effects of alpha2C-adrenoreceptor gene polymorphism in healthy humans
###end article-title 76
###begin article-title 77
Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure
###end article-title 77
###begin article-title 78
Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure
###end article-title 78
###begin article-title 79
Polymorphisms of cardiac presynaptic alpha2C adrenergic receptors: Diverse intragenic variability with haplotype-specific functional effects
###end article-title 79
###begin article-title 80
Genetic variation within the beta1-adrenergic receptor gene results in haplotype-specific expression phenotypes
###end article-title 80
###begin article-title 81
Statistical significance for genome-wide experiments
###end article-title 81
###begin article-title 82
###xml 45 53 <span type="species:ncbi:9606">patients</span>
Gene-expression profiles predict survival of patients with lung adenocarcinoma
###end article-title 82
###begin article-title 83
Searching for Disease-Susceptibility Loci by Testing for Hardy-Weinberg Disequilibrium in a Gene Bank of Affected Individuals
###end article-title 83
###begin article-title 84
###xml 45 49 <span type="species:ncbi:10090">mice</span>
Heterozygous alpha 2C-adrenoceptor-deficient mice develop heart failure after transverse aortic constriction
###end article-title 84
###begin article-title 85
Reliability of statistical associations between genes and disease
###end article-title 85
###begin article-title 86
Cross-validatory choice and assessment of statistical predictions
###end article-title 86
###begin article-title 87
Classification of gene microarrays by penalized logistic regression
###end article-title 87
###begin article-title 88
Multifactor dimensionality reduction for detecting gene-gene and gene-environment interactions in pharmacogenomics studies
###end article-title 88
###begin article-title 89
Epistatic effect of plasminogen activator inhibitor 1 and beta-fibrinogen genes on risk of glomerular microthrombosis in lupus nephritis: interaction with environmental/clinical factors
###end article-title 89
###begin article-title 90
Gene expression signature predicts recurrence in lung adenocarcinoma
###end article-title 90
###begin article-title 91
###xml 104 109 <span type="species:ncbi:9606">human</span>
A multivariate screening strategy for investigating metabolic effects of strenuous physical exercise in human serum
###end article-title 91
###begin article-title 92
Identification of diagnostic markers for tuberculosis by proteomic fingerprinting of serum
###end article-title 92
###begin article-title 93
Classification based upon gene expression data: Bias and precision of error rates
###end article-title 93
###begin article-title 94
Mass spectrometry proteomic diagnosis: enacting the double cross-validatory paradigm
###end article-title 94
###begin article-title 95
###xml 35 40 <span type="species:ncbi:9606">human</span>
Amino acid 49 polymorphisms of the human beta1-adrenergic receptor affect agonist-promoted trafficking
###end article-title 95

